# iovera° Professional (ioverapro.com) > ioverapro.com is the healthcare professional (HCP) resource for the iovera° cryoneurolysis system by Pacira BioSciences, Inc. The iovera° system is an FDA-cleared, non-surgical, drug-free treatment that delivers immediate pain relief up to 90 days by applying focused cold to peripheral nerves. This site provides clinical data, reimbursement guidance, training resources, and device information for healthcare professionals. ## About iovera° ### What is iovera° URL: https://www.ioverapro.com/what-is-iovera A handheld device that provides targeted, long-lasting pain relief through cryoneurolysis. Cryoneurolysis is the freezing of the signal-carrying parts of a nerve. The iovera° system creates a cold zone that blocks nerve signals and immediately reduces pain — without the use of drugs. Targeted cold is applied directly to a peripheral nerve. The iovera° treatment does not include the injection of opioids. Pain relief can last up to 90 days per treatment. iovera° uses nitrous oxide and the body's own fluid to create a precise cold zone under the skin cold enough to immediately prevent the nerve from sending pain signals without causing damage to the surrounding structures. The effect on the nerve is temporary, providing pain relief until the nerve regenerates and function is restored. The iovera° system is intended for use by, or under the direction of, a physician in settings such as a physician's office, ambulatory surgery center (ASC), or hospital-based outpatient department (HOPD). ### Appropriate Patients URL: https://www.ioverapro.com/appropriate-patients Many patients can benefit from the long-lasting pain relief of the iovera° treatment. Patient categories include: OA knee pain (patients with moderate OA chronically cycling through NSAIDs, injections, and opioids); pre-TKA prehabilitation and TKA rehabilitation and recovery (patients planning for TKA surgery, patients who hesitate or wish to delay surgery, patients concerned with pain limiting their postsurgical rehabilitation, patients with risk factors that need to be addressed prior to TKA, patients determined not to be surgical candidates); and other areas of the body — iovera° is being used for pain in areas including the hip, shoulder, ribs, foot and ankle, spine, and occipital. In addition, iovera° has a broad indication and is commonly used to treat pain in other areas: hip, rib, shoulder, foot and ankle, spine, head and neck, and mastectomy. ### The iovera° System URL: https://www.ioverapro.com/iovera-system Versatility by design. The iovera° system is intended for use by, or under the direction of, a physician in settings such as a physician's office, ambulatory surgery center (ASC), or hospital-based outpatient department (HOPD). It is used across operative and non-operative treatment pathways in specialties such as orthopedics, sports medicine, anesthesia, and pain management. The iovera° system is cleared to treat pain by targeting peripheral nerve tissue and may be used on nerves outside the knee, consistent with its indications for use. Three different Smart Tips give health care providers the flexibility to decide how to perform the treatment. Smart Tip options include: Smart Tip 2309, Smart Tip 2190 and Smart Tip 2190 With Nerve Stim, and Smart Tip 21180 With Nerve Stim. ## How It Works ### How iovera° Works URL: https://www.ioverapro.com/how-iovera-works The iovera° system uses N₂O, which does not reach temperatures cold enough to cause irreversible nerve damage. Liquid N₂O cartridge is inserted into the Handpiece; each cartridge >850 psi. During each treatment cycle, liquid N₂O flows into the attached Smart Tip, where it expands into a gas. The iovera° system uses the body's own fluids to form a precise cold zone around the nerve. N₂O boils at -88°C, which is the coldest temperature that can be attained with iovera°. N₂O safely exits as a gas; needles are closed-ended so nothing is injected into the body. ### Mechanism of Action URL: https://www.ioverapro.com/mechanism-of-action See how iovera° therapy works on the nerves that transmit pain signals. Cryoneurolysis with iovera° provides targeted pain relief without permanently damaging nerves. The treatment stages are: Treatment (cold zone is created around the targeted nerve, reaching a temperature of -88°C), Degeneration (cold zone causes degeneration of axon and myelin sheath, temporarily blocking nerve signals), Regeneration (following treatment, the axon regenerates at about 1 to 2 mm/day), and Reinnervation (the axon and myelin sheath are fully regenerated, and nerve signaling is restored). ### Comparison of Nerve Treatments URL: https://www.ioverapro.com/comparison-of-nerve-treatments Compared with cryoablation and cooled/conventional radiofrequency (RF), iovera° sits in a sweet spot at -88°C cryoneurolysis. Key comparisons: iovera° is cold enough to produce an immediate, long-lasting neurolytic block on the axon and myelin sheath of a peripheral nerve with 2nd degree (-100°C to -20°C) Sunderland Classification nerve degeneration. Unlike cryoablation, the cold is not too extreme to affect the structural components of the nerve. The axon regenerates along its original pathway at a rate of 1 to 2 mm per day until nerve signaling is fully restored. Cryoablation provides irreversible nerve degeneration via liquid nitrogen. Cryoneurolysis provides immediate treatment effect without permanently destroying nerves. RF risks neuroma formation postdenervation, neuritis, and injury to nearby tissue and vessels. ## Clinical Data ### OA Clinical Efficacy Data URL: https://www.ioverapro.com/oa-clinical-efficacy-data Up to 56% reduction in WOMAC pain scores from baseline. Treatment with iovera° helped patients get moving. Study design: randomized, double-blind, sham-controlled, multicenter trial with a 6-month follow-up in patients with knee OA. Significant improvements in physical function demonstrated at Day 30 (P=0.001), Day 60 (P=0.04), and Day 90 (P=0.017). Significant reduction in stiffness at Day 90 (P=0.03). Knee pain Clinical Practice Guideline cite Radnovich as a high quality study. The most common side effects were bruising, numbness, redness, tenderness on palpation, and swelling. Reference: Radnovich R et al. Osteoarthritis Cartilage. 2017;25(8):1247-1256. ### TKA Clinical Efficacy Data URL: https://www.ioverapro.com/tka-clinical-efficacy-data Less pain, fewer opioids. Significant pain reduction to help patients recover. 2x the improvement in KOOS symptom score (vs control group) at both week 6 and week 12 post-TKA. The iovera° group demonstrated significant reductions in PROMIS pain intensity and pain interference at 2- and 6-week follow-up, respectively (P<0.0001). 45% reduction in opioid consumption during the 12 weeks following surgery. Study design: retrospective chart review (N=100). Treatment group included first 50 patients treated with cryoneurolysis, plus multimodal treatment following its adoption in the practice for TKA. Control group was 50 patients treated with multimodal approach alone. Treatments were administered 5 days prior to the scheduled TKA. In this study, the most common side effect was bruising at the injection site. Reference: Dasa V et al. Knee. 2016;23(3):523-528. ## Reimbursement & Practice ### Reimbursement & Ordering URL: https://www.ioverapro.com/reimbursement Cryoneurolysis with iovera° is reimbursed in the Hospital Outpatient Department, Ambulatory Surgery Center, and Physician Office. CPT Code 64640: Destruction by neurolytic agent; other peripheral nerve or branch. CPT code 64640 is applicable to iovera° treatments applied to peripheral nerves and is used to bill for each of the peripheral nerve branches treated. CPT Code 64624: Destruction by neurolytic agent; genicular nerve branches including imaging; destruction of each of the following genicular nerve branches: superolateral, superomedial, and inferomedial. CPT 64624 defines all 3 of the specified nerves as 1 billable unit. iovera° is part of the NOPAIN Act. Medicare provides separate reimbursement for iovera° in outpatient settings (both ASC and HOPD) when using code C9809. Reimbursement Helpline: 855-793-9727 or reimbursement@pacira.com. ### NOPAIN Act URL: https://www.ioverapro.com/nopain-act The NOPAIN (Non-Opioids Prevent Addiction in the Nation) Act was enacted to expand access to non-opioid pain treatments for Medicare patients to help reduce opioid use and combat the opioid epidemic. As of January 1, 2025, under a final rule from Centers for Medicare and Medicaid Services (CMS), iovera° is officially recognized as a qualifying non-opioid device eligible for separate Medicare reimbursement under the NOPAIN Act. Hospitals and ambulatory surgical centers will receive an additional payment of up to $261.38 — beyond what they might already get for a procedure — when they bill with the unique C-code for iovera°, C9809. The NOPAIN Act is valid for procedures through December 31, 2027. For Medicare recipients, this makes non-opioid pain options like iovera° more accessible. For providers/hospitals, this reduces the financial disincentive to use non-opioid therapies and encourages adoption of safer, opioid-sparing pain management options. ### FlexForward Overview URL: https://www.ioverapro.com/flexforward FlexForward® is designed to help you get commercial and Medicare Advantage patients started with iovera°. It provides comprehensive reimbursement support through benefits investigation help, prior authorization and appeals support, and coding and billing assistance. Services include: benefits investigations with coverage determination within 24 to 72 hours; prior authorizations and appeals support with guidance navigating these processes; and coding and billing assistance with information, training, and support to help verify the appropriate codes to use based on your patients' health insurance. Get started today at FlexForward.com. ## Educational Resources ### Video Library URL: https://www.ioverapro.com/video-library Training and educational videos for healthcare professionals. Learn treatment techniques and clinical applications through educational content. ### Recorded Hands-On Training URL: https://www.ioverapro.com/training Recorded hands-on training videos for healthcare professionals. Learn treatment techniques and clinical applications through educational content. ### Administrative Case Reports URL: https://www.ioverapro.com/administrative-case-reports Administrative case reports for iovera° treatments. Clinical documentation examples and case studies for healthcare providers. Includes the Comparative Technology Guide — a side-by-side educational comparison of available thermal neurolytic treatments. ### Peer Testimonials URL: https://www.ioverapro.com/peer-testimonial Hear from physicians using iovera° in clinical practice. Real-world implementation insights and practitioner perspectives. ### Practice Toolkit URL: https://www.ioverapro.com/practice-toolkit The iovera° Practice Toolkit includes a variety of resources designed to help educate patients and promote iovera° for your practice. ## Additional Resources ### FAQ URL: https://www.ioverapro.com/faq Frequently asked questions organized into 8 categories: **New to iovera°?** Q: I'm interested in iovera° treatment. Who can I contact to learn more? A: On iovera.com, click on the Contact Us link for more information. Pacira BioSciences, Inc. has developed a large network of experienced providers who can give you more information. The PITT Training Center, located in Tampa, provides opportunities for continuing education and hands-on training with the iovera° device. Q: What are the benefits of iovera° treatment compared with traditional pain management protocols? A: iovera° provides sustained relief of OA and TKA pain, decreasing the need for chronic adjuvant medications such as opioids. While traditional pain management options serve a purpose, many patients are happy to avoid the side effects associated with narcotic use to control pain. **Mechanism of Action** Q: How does iovera° treatment work? A: iovera° temporarily freezes nerves in the pain-signaling pathway, providing patients with pain relief for up to 90 days. Q: Is iovera° treatment the same as conventional radiofrequency (RF) and cryoablation? A: No, iovera° causes second-degree Wallerian degeneration, which means that nerves regain function over time without fear of irreversible nerve destruction or painful neuromas. Q: Does iovera° treatment permanently destroy nerves? A: No, the effect of iovera° does not cause permanent nerve damage to the exterior nerve structure. It causes second-degree Wallerian degeneration, which means that nerves regain function over a period of time. This allows for successful pain relief with minimal-to-no risk of neuritis. **Results** Q: What clinical study data do you have for presurgical use of iovera° treatment in TKA? A: Dasa et al, in a single-site retrospective study of 100 patients where 50 patients in the treatment group received iovera° and 50 in the control group did not, demonstrated that patients treated with iovera° before TKA had a shorter length of stay and decreased opioids prescribed compared with a standard of care treatment group. Q: What are the study data for iovera° treatment? A: We continue to be fueled by studies that demonstrate the value of iovera°, as well as countless real-world success stories that range from decreased or eliminated opioid consumption and a faster road to rehabilitative therapy, to discharge on the same day of surgery. **Patient Considerations** Q: What should my patients expect from iovera° treatment? A: With iovera°, patients can expect up to 3 months of relief from OA pain. Q: Is iovera° treatment painful? A: Treatment with iovera° is minimally painful. After the area is numbed, treatment is virtually painless. Q: Can the use of iovera° help decrease my patients' need for opioids post-TKA? A: Yes, clinical studies have shown that treatment with iovera° can significantly decrease the need for opioids post-TKA. Q: What sort of pain relief can patients expect with iovera° treatment? A: Most patients treated with iovera° report significant relief of OA knee pain. In fact, iovera° allows many of these patients to delay TKA. For patients who do undergo surgery, iovera° has been shown to provide significant pain relief and a decreased need for opioids. **Device** Q: Does treatment with iovera° need to be performed by the surgeon or anesthesiologist, or can other members of staff administer the treatment? A: After proper training, health care staff beyond the surgeon or anesthesiologist can administer treatment with iovera° if state regulations allow. Q: Can iovera° be used for deeper nerves or structures? A: Yes, it can. In principle, any sensory peripheral nerve that can be blocked with local anesthetic can potentially be treated with iovera°. For example, it can be used for deep genicular blocks for chronic OA knee pain. Always be aware of adjacent nerves that could be within the cryogenic freeze zone when considering the use of iovera° for a specific nerve block. **Cost and Coverage** Q: How is iovera° reimbursed? A: Pacira BioSciences, Inc., has a dedicated reimbursement hotline to help determine the reimbursement policies in your region. As with most procedures, iovera° treatment reimbursement may vary; however, using specific provided codes can improve payment and reimbursement for the services rendered. Q: What is the capital investment for implementing iovera° in my practice? A: Pacira BioSciences, Inc., has a mission to provide high-quality, low-cost, opioid-sparing alternatives for physicians and patients. The costs associated with the iovera° treatment system are not prohibitive, and individualized capital investment conversations can help ensure that all patients receive the highest quality care. **General Reimbursement Information** Q: Can the Reimbursement Helpline help me with the proper verbiage on clinical notes and billing submissions? A: Yes. Dedicated specialists are available to: provide the applicable codes, the reimbursement amount or fee schedule, and the specific coding requirements; assist with reviewing operative reports to ensure medical necessity is captured and applicable CPT codes are submitted; fulfill requests for coding education; and research commercial payers policy regarding cryoneurolysis and iovera°. Q: What is the best way to maximize my iovera° reimbursement? A: As you know, you will base iovera° use on your clinical determination of which nerves need to be treated and not on reimbursement. Q: How can my practice get reimbursed to cover the cost of iovera°? A: We are unable to talk about pricing and reimbursement in the same discussion. We are, however, permitted to discuss various pricing and contracting options for iovera° unrelated to reimbursement. We can also review reimbursement associated with iovera° based on your clinical judgment about which nerves will be treated. Q: Does the professional component rate for iovera° apply to Physician Assistants? A: The professional component rates of CPT 64640 and 64624 in RVUs for Medicare are the same for either an MD or a DO. However, billing for Physician Assistant (PA) services is handled differently throughout the country. Generally, Medicare will defer to state laws regarding billing for PAs. Some private carriers want the PA credentialed. Other private carriers will advise billing under the supervising physician's National Provider Identifier. Please direct PA-related questions to the Reimbursement Helpline at reimbursement@pacira.com. Q: Is it necessary to provide the site of care where the iovera° treatment is performed? A: The specific site of care should be noted (eg, office, operating room, postanesthesia care unit, etc) in your operative note. If the procedure is performed in a hospital outpatient department (HOPD) vs an office, but both are in the same building, the site of care listed should represent the specific area of the building where the procedure is performed. Q: If I used radiofrequency to treat a patient and billed CPT 64624, can I re-treat the patient using CPT 64624 for an iovera° treatment? A: The Medicare guidelines do not definitively state whether there is a limit on how many times a year you can bill CPT 64624. The procedure needs to be supported by medical necessity, including comprehensive clinical documentation with specific nerves being treated and the diagnosis code. Contact the Reimbursement Helpline to review the situation prior to performing the treatment. Q: If a doctor performs iovera° treatment on the same day as TKA, does it prevent the facility from capturing the facility fee? A: Unless there is a contract that includes bundling of procedures, the facility fee would apply to the CPT codes for the iovera° treatments and the TKA CPT code. The ICD-10-CM diagnosis code does not affect whether a CPT is captured in an outpatient setting. The global period for CPT 64640 and 64624 is 10 days, which may impact the TKA reimbursement if performed on the same day. Contact the Reimbursement Helpline for guidance. Q: When treating the 3 nerves for AFCN, ISN, and deep genicular nerve, what would be the total RVUs? A: If the documentation indicates that the AFCN and ISN are being treated, this would be considered 2 separate nerves. If the deep genicular nerves are being treated, it would be considered 1 nerve. Based on the 3 nerves treated, the work RVUs would be 6.46 work RVUs. Some hospitals may have different RVUs assigned than the Medicare RVUs. Q: Can iovera° be performed on the same day as a TKA procedure, and would my practice be reimbursed for both? A: Although cryoneurolysis CPT codes applicable for iovera° treatments are not bundled into the TKA code by Medicare, there is no guarantee of reimbursement for both procedures on the same date of service. The global period for CPT 64640 and CPT 64624 is 10 days. Modifiers may also be needed to bill these procedures on the same day. Commercial payer policies vary. Contact the Reimbursement Helpline for guidance. Q: Can both the superficial and deep genicular nerves be treated during the same session? A: Yes, superficial genicular nerves and deep genicular nerves can be treated in 1 session. Use CPT 64640 for the superficial nerves treated and CPT 64624 for deep genicular nerves (superolateral, superomedial, and inferomedial). Modifier 51 may be required, and some commercial payers may require Modifier 59. 64624 should be listed first since it has the highest RVU. **Insurance/Payer Information** Q: Does Medicare limit how many times CPT 64640 can be billed per year? A: The Medicare guidelines do not definitively state whether there is a limit on how many times a year you can bill CPT 64640. The procedure needs to be supported by medical necessity, including comprehensive clinical documentation with specific nerves being treated and the diagnosis code. Contact the Reimbursement Helpline to review the situation. Q: Do Medicare Advantage plans reimburse iovera° treatments? A: In general, Medicare Advantage plans follow Medicare coverage rules. Medicare Advantage plans are considered Medicare Part C, which includes what is covered in Medicare Parts A and B. Q: Which commercial payers are reimbursing iovera°? A: iovera° reimbursement varies across commercial payers and may evolve with time as evidenced by updates on their policies. In addition, some commercial payers have reimbursement policies that vary by state. Please contact reimbursement specialists through the Reimbursement Helpline at 855-793-9727 or reimbursement@pacira.com. Q: What is the Medicare reimbursement rate for my specific city? A: The reimbursement rates provided in the iovera° Coding and Reimbursement Guide represent Medicare's national average rates. Your biller or administrator can access local market information through their local Medicare entity (fiscal intermediary or Medicare Administrator Contractor). The Reimbursement Helpline at 855-793-9727 or reimbursement@pacira.com can provide additional support. ### Find a Doctor Registration URL: https://www.ioverapro.com/find-a-doctor-registration Patients are looking for an immediate, long-lasting, non-surgical solution for pain. Sign up for the iovera° Find a Doctor Program to make it easier for patients in your area to find you. ### Schedule a Demo URL: https://www.ioverapro.com/schedule-demo Reimagine pain relief with iovera°. Get a personalized iovera° demo tailored to your specialty and patient needs — see how it can elevate your care approach. ### Instructions for Use URL: https://www.ioverapro.com/instructions-for-use Carefully read all instructions prior to using the iovera° system. Observe all contraindications, warnings, and cautions noted throughout the guide. ### Contact Us URL: https://www.ioverapro.com/contact-us Contact Pacira for iovera° professional support. ### Medial Branch URL: https://www.ioverapro.com/medial-branch Introducing the latest innovation in the iovera° Smart Tip portfolio. With the iovera° Spine Smart Tip, you can target medial branch nerves to provide immediate, long-lasting relief from chronic back pain — the number one indication for opioid prescriptions in the US. It provides a compelling alternative to treatments such as radiofrequency ablation (RFA), which can damage surrounding tissue and blood vessels and may not always provide immediate pain relief. ### Pain with Spasticity URL: https://www.ioverapro.com/pain-with-spasticity Managing pain associated with spasticity may positively impact the quality of life and well-being of patients. Given the high occurrence of pain in patients with spasticity, managing it should be an integral part of the patient treatment plan. ## Key Clinical References 1. Radnovich R et al. Osteoarthritis Cartilage. 2017;25(8):1247-1256. 2. Dasa V et al. Knee. 2016;23(3):523-528. 3. Ilfeld BM et al. Br J Anaesth. 2017;119(4):703-706. 4. Plessl D et al. J Am Acad Orthop Surg. 2020;28(21):e962-e968. ## Important Safety Information **Indication:** The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. When stimulation compatible components are used, the iovera° system can also facilitate target nerve location by conducting electrical nerve stimulation from a compatible 3rd party nerve stimulator. **Contraindications:** The iovera° system is contraindicated for use in patients with the following: cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and open and/or infected wounds at or near the treatment site. **Potential Complications:** As with any surgical treatment that uses needle-based therapy and local anesthesia, there is a potential for site-specific reactions, including, but not limited to: ecchymosis, edema, erythema, local pain and/or tenderness, and localized dysesthesia. Proper use of the device as described in the User Guide can help reduce or prevent the following complications: - At the treatment site(s): injury to the skin related to application of cold or heat, hyper- or hypopigmentation, and skin dimpling. - Outside the treatment site(s): loss of motor function. For full prescribing information, see the [Instructions for Use](https://www.ioverapro.com/instructions-for-use). ## Contact Information - Website: https://www.ioverapro.com - Patient Website: https://www.iovera.com - Reimbursement Helpline: 855-793-9727 - Reimbursement Email: reimbursement@pacira.com - Manufacturer: Pacira BioSciences, Inc.